Multivessel Coronary Artery DiseaseEVERESTNCT06740552
Evolocumab in Patients With Multivessel Coronary Disease After Acute Myocardial Infarction: A Target Trial Emulation
An observational study of Multivessel Coronary Artery Disease and Acute Myocardial Infarction (AMI), run by Shanghai Zhongshan Hospital at 1 site in China.
Trial summary
The goal of this Target Trial Emulation (TTE) study is to evaluate the effect of evolocumab on clinical prognosis in patients with multivessel disease (MVD) following acute myocardial infarction (AMI) who have deferred non-culprit vessel. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multivessel Coronary Artery Disease, Acute Myocardial Infarction (AMI)
- What is being tested?
- Evolocumab and Lipid Lowering Medication
- How many people
- 1,862 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2021to 31 Oct 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This is a TTE study based on a multicentered, consecutive cohort of AMI patients from 2021 to 2022 at five 3rd-tier hospital in Shanghai. Patients who were diagnosed as AMI and refferred to primary invasive coronary angiography are consecutively enrolled in this cohort, regardless of revascularization treatment and lipid lowering strategy. The five hospitals are Zhongshan Hospital, Renji Hospital, Tongji Hospital, Shanghai General Hospital, and Shanghai Tenth People's Hospital.
Who may be able to join
- Age ≥18 years old;
- Acute myocardial infarction diagnosed at hospital admission;
- Multivessel coronary artery disease diagnosed at primary invasive coronary angiography;
- Culprit vessel successfully revascularized;
- At lease 1 non-culprit vessel with ≥50% stenosis and deferred at the opinion of the operator, and no staged revascularization within 6 months.
Who cannot join
- Cardiac shock, hemodynamically unstable, or severe heart failure (Killip IV)
- Any cardiac surgery within 6 weeks prior to screening;
- Moderate to severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m^2 at screening;
- Contraindication or allergy to iodinated contrast agent;
- Malignancy except non-melanoma skin cancers, cervical, or breast ductal carcinoma in situ within the last 5 years;
- Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed in short term.
Trial locations and contacts
1 site in 1 country.
China1 site
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200000
About this study
Official title: Effect of Evolocumab on Non-culprit Coronary Lesions in Patients With Multivessel Disease Following Acute Myocardial Infarction: A Target Trial Emulation
The goal of this Target Trial Emulation (TTE) study is to evaluate the effect of evolocumab on clinical prognosis in patients with multivessel disease (MVD) following acute myocardial infarction (AMI) who have deferred non-culprit vessel. The main question it aims to answer is:
Does evolocumab lower risks of major adverse cardiovascular events (MACE) in patients with deferred non-culprit vessel after AMI?
Read the detailed description
This study aims to investigate the potential prognostic benefits of evolocumab in patients with MVD after AMI at 2-year follow-up. The primary endpoint is MACE, defined as a composite of cardiac death, myocardial infarction, stroke, angina-driven coronary revascularization, and rehospitalization for heart failure. This is a multicentre, cohort-based TTE study and the target RCT is the FOURIER trial.
- Being tested
- Evolocumab, Lipid Lowering Medication
- Keywords
- evelocumab, non-culprit vessel, multivessel coronary artery disease, acute myocardial infarction, outcome, target trial emulation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EvolocumabDrug
Evolocumab 140mg every two weeks
Lipid Lowering MedicationDrug
Any lipid lowering medication, including statin, ezetimibe, fibrates and etc.
| Study group | Role | What they receive |
|---|---|---|
| TTE cohort | The TTE cohort is the finally anlyzed population. The participates are enrolled upon meeting the inclusion/exclusion criteria. Receives: Drug: Evolocumab; Drug: Lipid Lowering Medication |
What is being measured
The primary outcome is the main question the study is designed to answer.
MACE
A composite of cardiac death, myocardial infarction, and rehospitalization for heart failure.
Measured: 2 years
Secondary outcomes (3)
Death
All-cause death
Measured: 2 years
Myocardial infarction
Myocardial infarction denotes the presence of acute myocardial injury detected by abnormal cardiac biomarkers in the setting of evidence of acute myocardial ischemia, according to the Fourth Universal Definition of Myocardial Infarction (2018).
Measured: 2 years
Rehospitalization for heart failure
Readmissions due to symptoms from clinically diagnosed heart failure with or without reduced left ventricular ejection fraction.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Dec 2024
- Study start1 Jan 2021
- Primary completion31 Dec 2024
- Study completion31 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Multivessel Coronary Artery DiseaseStudies of the same condition, open and under way.
- More trials run by Shanghai Zhongshan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,862 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shanghai Zhongshan Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Shanghai Shen Kang Hospital Development Center, Tongji Hospital, RenJi Hospital, Shanghai 10th People's Hospital, Shanghai General Hospital, China
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06740552
- Sponsor's protocol ID
- SHDC2024CRI050
- Acronym
- EVEREST
- Status last verified
- Oct 2025
- First submitted
- 15 Dec 2024
- Last updated
- 2 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: IPD is under protection and surveilliance of Shanghai Hospital Development Ceter.
Publications
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
PubMed 28304224
Study at a glance
From the registry record, last updated by the sponsor on 2 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Evolocumab on Non-culprit Coronary Lesions in Patients With Multivessel Disease Following Acute Myocardial Infarction: A Target Trial Emulation
- ClinicalTrials.gov ID
- NCT06740552
- Acronym / sponsor ID
- EVEREST / SHDC2024CRI050
- Keywords
- evelocumab, non-culprit vessel, multivessel coronary artery disease, acute myocardial infarction, outcome, target trial emulation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,862 participants (actual)
- Lead sponsor
- Shanghai Zhongshan HospitalUniversity, hospital or other
- Collaborators
- Shanghai Shen Kang Hospital Development Center, Tongji Hospital, RenJi Hospital, Shanghai 10th People's Hospital, Shanghai General Hospital, China
- Study start
- 1 Jan 2021 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 Oct 2025 (actual)
- First posted
- 18 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this Target Trial Emulation (TTE) study is to evaluate the effect of evolocumab on clinical prognosis in patients with multivessel disease (MVD) following acute myocardial infarction (AMI) who have deferred non-culprit vessel. The main question it aims to answer is:
Does evolocumab lower risks of major adverse cardiovascular events (MACE) in patients with deferred non-culprit vessel after AMI?
Detailed description
This study aims to investigate the potential prognostic benefits of evolocumab in patients with MVD after AMI at 2-year follow-up. The primary endpoint is MACE, defined as a composite of cardiac death, myocardial infarction, stroke, angina-driven coronary revascularization, and rehospitalization for heart failure. This is a multicentre, cohort-based TTE study and the target RCT is the FOURIER trial.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| TTE cohort | – | Drug: Evolocumab, Drug: Lipid Lowering MedicationThe TTE cohort is the finally anlyzed population. The participates are enrolled upon meeting the inclusion/exclusion criteria. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This is a TTE study based on a multicentered, consecutive cohort of AMI patients from 2021 to 2022 at five 3rd-tier hospital in Shanghai. Patients who were diagnosed as AMI and refferred to primary invasive coronary angiography are consecutively enrolled in this cohort, regardless of revascularization treatment and lipid lowering strategy. The five hospitals are Zhongshan Hospital, Renji Hospital, Tongji Hospital, Shanghai General Hospital, and Shanghai Tenth People's Hospital.
Key inclusion criteria (5 listed)
- Age ≥18 years old;
- Acute myocardial infarction diagnosed at hospital admission;
- Multivessel coronary artery disease diagnosed at primary invasive coronary angiography;
- Culprit vessel successfully revascularized;
- At lease 1 non-culprit vessel with ≥50% stenosis and deferred at the opinion of the operator, and no staged revascularization within 6 months.
Key exclusion criteria (6 listed)
- Cardiac shock, hemodynamically unstable, or severe heart failure (Killip IV)
- Any cardiac surgery within 6 weeks prior to screening;
- Moderate to severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m^2 at screening;
- Contraindication or allergy to iodinated contrast agent;
- Malignancy except non-melanoma skin cancers, cervical, or breast ductal carcinoma in situ within the last 5 years;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EvolocumabEvolocumab 140mg every two weeks | Drug | TTE cohort |
| Lipid Lowering MedicationAny lipid lowering medication, including statin, ezetimibe, fibrates and etc. | Drug | TTE cohort |
Primary outcome
MACE
Time frame: 2 years
A composite of cardiac death, myocardial infarction, and rehospitalization for heart failure.
3 secondary outcomes
Death
Time frame: 2 years
Myocardial infarction
Time frame: 2 years
Rehospitalization for heart failure
Time frame: 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Feb 2026.
- Results publication: PubMed 28304224Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
- Individual participant dataSharing planned: No. IPD is under protection and surveilliance of Shanghai Hospital Development Ceter.
Related trials for Multivessel Coronary Artery Disease
Recruiting
Multivessel Balloon Occlusion to Investigate Obstructive Coronary Artery Disease and aNgina
Stable Angina, Multivessel Coronary Artery Disease
Recruiting
Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)
Myocardial Infarction (MI)
Active, not recruiting
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
Acute Myocardial Infarction, Coronary Artery Disease
Recruiting
Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD
Multi Vessel Coronary Artery Disease, Percutaneous Coronary Intervention
Active, not recruiting
Medical Management vs Partial Revascularization in Diffuse Multivessel Coronary Artery Disease
Multi Vessel Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multivessel Coronary Artery Disease and Acute Myocardial Infarction (AMI), run by Shanghai Zhongshan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MACE (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06740552, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2026.